Claims
- 1. A substantially pure and isolated N-formyl paroxetine of formula (1)
- 2. The compound according to claim 1, wherein said compound is in the form of an oil.
- 3. The compound according to claim 1, wherein said compound contains not greater than 10% impurities.
- 4. The compound according to claim 1, wherein said N-formyl paroxetine is the trans-3S, 4R enantiomer.
- 5. A composition which comprises an N-formyl paroxetine of formule (1). and 0.1% to 99.97% of a paroxetine compound, based on the combined weight of said N-formyl paroxetine and said paroxetine compound.
- 6. The composition according to claim 5, which comprises 1% to 99.89% of said paroxetine compound.
- 7. The composition according to claim 6, which comprises 1% to 99.8% of said paroxetine compound.
- 8. The composition according to claim 7, which comprises 10% to 99.7% of said paroxetine compound.
- 9. The composition according to claim 5, wherein said paroxetine compound is selected from the group consisting of paroxetine, paroxetine hydrochloride, paroxetine maleate, paroxetine acetate, and paroxetine mesylate.
- 10. The composition according to claim 5, which further comprises a pharmaceutically acceptable excipient.
- 11. The composition according to claim 10, wherein said at least one excipient comprises a calcium phosphate.
- 12. A pharmaceutical composition for treating a selective serotonin reuptake inhibitor-treatable disease or condition, comprising an effective amount of a paroxetine agent and at least one pharmaceutically acceptable excipient, wherein said paroxetine agent consists of an N-formyl paroxetine compound of formula (1) and 0 to 99,97 % of a paroxetine compound, based on the combined weight of said N-formyl paroxetine and said paroxetine compound:
- 13. A composition comprising a N-formyl Paroxetine of formula (1), 0 to 99.97% of a paroxetine compound, based on the combined weight of said N-formyl paroxetine and said paroxetine compound, and at least one ingredient selected from the group consisting of binders, fillers, carriers, preservatives, and combinations thereof.
- 14. The composition according to claim 13, wherein said composition contains 0 to 5% of paroxetine compound.
- 15. The composition according to claim 13, wherein said composition is in a liquid form.
Parent Case Info
This application claims the benefit of priority under 35 U.S.C. §119(e) from Provisional Application No. 60/330,430, filed Oct. 22, 2001, the entire contents of which are incorporated herein be reference.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4007196 |
Christensen et al. |
Feb 1977 |
A |
4721723 |
Barnes et al. |
Jan 1988 |
A |
6239126 |
Kelly et al. |
May 2001 |
B1 |
Foreign Referenced Citations (11)
Number |
Date |
Country |
0223403 |
Aug 1993 |
EP |
0812829 |
Jun 1996 |
EP |
802185 |
Apr 1997 |
EP |
1074550 |
Jul 2000 |
EP |
WO 9546448 |
Jun 1995 |
WO |
WO9853824 |
Dec 1998 |
WO |
WO 9958113 |
Nov 1999 |
WO |
WO0026187 |
May 2000 |
WO |
WO0104093 |
Jan 2001 |
WO |
WO0104093 |
Jan 2001 |
WO |
WO 0217921 |
Mar 2002 |
WO |
Non-Patent Literature Citations (1)
Entry |
Fox et al. “Physics and chemistry of the organic solid state” Intersci. Pubs. p. 179-182 (1963). |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/330430 |
Oct 2001 |
US |